Publication | Closed Access

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

MedicineInterim Survival AnalysisMetronomic TherapyClinical TrialsMetastatic NsclcFirst-line TreatmentPharmacotherapyCancer TreatmentOncologyRadiation OncologyHealth Sciences